NASDAQ · Key Statistics

Akebia Therapeutics, Inc. (AKBA) Key Statistics

$0.57 NASDAQ: AKBA Market Cap $157.09M

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Akebia Therapeutics, Inc. (AKBA), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

Metric	Value
P/E ratioShare price divided by earnings per share.	-8.01
P/B ratioShare price divided by book value per share.	9.32
P/S ratioMarket value divided by annual revenue.	1.06
PEG ratioP/E divided by the earnings growth rate.	0.02
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.	-7.24
EV / RevenueEnterprise value against annual revenue.	0.60
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.	-10.99%
Free cash flow yieldFree cash flow as a percentage of market value.	17.34%
Price / free cash flowMarket value divided by free cash flow.	3.41

Profitability

Metric	Value
Gross marginRevenue left after the direct cost of goods sold.	79.48%
Operating marginRevenue left after operating costs.	-6.91%
Net marginRevenue left after every cost, including tax and interest.	-13.54%
Return on equityProfit as a percentage of shareholders’ equity.	-93.74%
Return on assetsProfit as a percentage of total assets.	-8.48%
Return on capital employedOperating profit against the capital the business uses.	-8.01%

Financial health

Metric	Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.	1.43
Quick ratioThe same, excluding inventory.	1.35
Cash ratioCash alone against current liabilities.	1.13
Debt to equityTotal borrowings against shareholders’ equity.	2.16
Debt to assetsTotal borrowings against total assets.	0.57
Interest coverageHow many times operating profit covers the interest bill.	-1.90

Per share and size

Metric	Value
Earnings per shareProfit attributable to each share.	$-0.02
Book value per shareShareholders’ equity divided by shares outstanding.	$0.00
Shares outstandingShares currently issued.	0
Market capitalisationShare price times shares outstanding.	$157.09M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.	$60.19M
EmployeesReported headcount.	181

Dividend

Metric	Value
Dividend yieldAnnual dividend as a percentage of the share price.	0.00%

Akebia Therapeutics, Inc. (AKBA) statistics — frequently asked questions

What is Akebia Therapeutics, Inc.'s P/E ratio?

Akebia Therapeutics, Inc. (AKBA) trades on a price-to-earnings ratio of -8.01. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Akebia Therapeutics, Inc.'s return on equity?

Akebia Therapeutics, Inc. (AKBA) reports a return on equity of -93.74%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Akebia Therapeutics, Inc. carry?

Akebia Therapeutics, Inc. (AKBA) has a debt-to-equity ratio of 2.16, which compares total borrowings with shareholders' equity.

What is Akebia Therapeutics, Inc.'s profit margin?

Akebia Therapeutics, Inc. (AKBA) keeps -13.54% of revenue as net profit after every cost, including tax and interest.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.